System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Jean-Jacques Grob is an expert in Dermatology at Hôpitaux universitaires de Marseille (France). As of October 2026, ScienceLeadR ranks Jean-Jacques Grob in the top 1% of experts worldwide for Skin Neoplasms, Melanoma and Carcinoma. Jean-Jacques Grob has authored 822 publications, the most recent in 2026, and is an investigator in 53 clinical trials, 1 of them ongoing. SLR score: 3,104 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Jean-Jacques Grob Hôpitaux universitaires de Marseille France
3 104 ScienceLeadR Reputation 3104

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Oncology - Biochemistry

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 1987 - 2026
Source: PubMed

Aix-Marseille University

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 822

Citations

Citations: 91 592 1st author: 95 Last author: 103 Unique author: 21

Main journals

Ann Dermatol Venereol 202
J Clin Oncol 111
Ann Oncol 65
Eur J Cancer 64
Lancet Oncol 25

Best Journals

J Clin Oncol 60
Ann Oncol 30
Lancet Oncol 25

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Real-World Use of Adjuvant Nivolumab for Resected Stage III-IV Melanoma: 2-Year Analysis of AdjuMel.
PMID 42667537 — safety, melanoma, nivolumab, therapeutics		Dermatol Ther (Heidelb)20260
Administration of nivolumab plus ipilimumab: Infusion of the fixed-ratio combination versus sequential infusions in two randomized controlled trials of metastatic melanoma (CheckMate 742) and renal cell carcinoma (CheckMate 800).
PMID 40614118 — cells, safety, incidence, melanoma, neoplasms, carcinoma, renal cell, immune checkpoint inhibitors, nivolumab, ipilimumab		Cancer20250
Erratum: Randomized, Open-Label, Phase III Study of Tilsotolimod in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced Refractory Melanoma (ILLUMINATE-301).
PMID 40561410 — melanoma, ipilimumab		J Clin Oncol Top journal20251
Efficacy of adjuvant therapy in patients with stage IIIA cutaneous melanoma.
PMID 40204154 — melanoma, neoplasms, immunotherapy, therapeutics		Ann Oncol Top journal20250
A Phase I, First-in-Human, Dose-Escalation, Expansion Trial of Cytokine-Encoding Synthetic mRNA Mixture Alone or with Cemiplimab in Advanced Solid Tumors.
PMID 40152791 — cytokines, neoplasms, rna, messenger, therapeutics		Clin Cancer Res20250

Clinical Studies 53

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 6

By phase:

Phase 3 28
Phase 2 14
Phase 1 4
N/A 3
Phase 1/Phase 2 2
Phase 2/Phase 3 1
Phase 4 1

By status:

Completed 36
Terminated 7
Active not recruiting 5
Recruiting 3
Unknown 2

By type:

Interventional 50
Observational 3

By Monocentric/Multicentric:

monocentric 6
multicentric2to4 0
multicentric5to9 1
multicentricup10 46

Main Topics

Cohort/Consortium Investigators 2

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
L19IL2 L19TNF in Skin Cancer Patients
NCT05329792 — keratoacanthoma, skin, cells, sarcoma, kaposi, merkel cells, carcinoma, squamous cell, lymphoma, neoplasms, sarcoma, lymphoma, t-cell, cutaneous, therapeutics, t-lymphocytes, carcinoma, basal cell, carcinoma, merkel cell, skin neoplasms, lymphoma, t-cell, carcinoma		Phase 2Recruiting2023

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS